BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, Calvieri S, Richetta AG. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases 2016; 4(2): 49-55 [PMID: 26881191 DOI: 10.12998/wjcc.v4.i2.49]
URL: https://www.wjgnet.com/2307-8960/full/v4/i2/49.htm
Number Citing Articles
Diana Velázquez Tarjuelo, Pablo de la Cueva Dobao. Certolizumab in a patient with severe psoriasis and concomitant hepatitis C virus infectionJAAD Case Reports 2018; 4(8): 833 doi: 10.1016/j.jdcr.2018.06.003
Lin Li, Xian Jiang, Lixin Fu, Liwen Zhang, Yanyan Feng. Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysisClinical and Experimental Medicine 2022; 23(3): 701 doi: 10.1007/s10238-022-00827-y
S.A.R. Siegel, K.L. Winthrop, B.D. Ehst, A. Ortega Loayza. Ustekinumab use in patients with severe psoriasis co‐infected with hepatitis B and/or CBritish Journal of Dermatology 2019; 180(5): 1232 doi: 10.1111/bjd.17444
Claudio Bonifati, Viviana Lora, Dario Graceffa, Lorenzo Nosotti. Management of psoriasis patients with hepatitis B or hepatitis C virus infectionWorld Journal of Gastroenterology 2016; 22(28): 6444-6455 doi: 10.3748/wjg.v22.i28.6444
Igor Snast, Lihi Atzmony, Marius Braun, Emmilia Hodak, Lev Pavlovsky. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literatureJournal of the American Academy of Dermatology 2017; 77(1): 88 doi: 10.1016/j.jaad.2017.01.037
Giovanni Damiani, Chiara Franchi, Paolo Pigatto, Andrea Altomare, Alessia Pacifico, Stephen Petrou, Sebastiano Leone, Maria Caterina Pace, Marco Fiore. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agentsWorld Journal of Hepatology 2018; 10(2): 329-336 doi: 10.4254/wjh.v10.i2.329
Virginia Martinez-Santana, Esther Rodriguez-Murphy, Alex Smithson, Nuria Miserachs-Aranda, Ruben del Río-Gil, Inmaculada Torre-Lloverás. Efficacy and safety of direct-acting antiviral agents when combined with secukinumabEuropean Journal of Hospital Pharmacy 2018; 25(1): 53 doi: 10.1136/ejhpharm-2017-001212
Nawaf AlMutairi, Hesham Alaadin Abouzaid. Safety of biologic agents for psoriasis in patients with viral hepatitisJournal of Dermatological Treatment 2018; 29(6): 553 doi: 10.1080/09546634.2018.1430301
Loris Lopetuso, Giammarco Mocci, Manuela Marzo, Francesca D’Aversa, Gian Rapaccini, Luisa Guidi, Alessandro Armuzzi, Antonio Gasbarrini, Alfredo Papa. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the LiverInternational Journal of Molecular Sciences 2018; 19(8): 2199 doi: 10.3390/ijms19082199
Claudia Lindhaus, Jörg Tittelbach, Peter Elsner. Nebenwirkungen von TNF‐alpha‐Inhibitoren am HautorganJDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017; 15(3): 281 doi: 10.1111/ddg.13200_g
Claudia Lindhaus, Jörg Tittelbach, Peter Elsner. Cutaneous side effects of TNF‐alpha inhibitorsJDDG: Journal der Deutschen Dermatologischen Gesellschaft 2017; 15(3): 281 doi: 10.1111/ddg.13200
Alexandra Garten Schmitt, Thomas Erwes, Lisa M. Chirch. Inflammatory Bowel DiseaseClinical Gastroenterology 2021; : 137 doi: 10.1007/978-3-030-81780-0_6